{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T07:55:36Z","timestamp":1791705336492,"version":"4.3.4"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012360","name":"Heart of England NHS Foundation Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012360","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.rmed.2025.107995","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T21:59:00Z","timestamp":1739656740000},"page":"107995","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Optimising outcomes for adults with cystic fibrosis taking CFTR modulators by individualising care: Personalised data linkage to understand treatment optimisation (PLUTO), a novel clinical framework"],"prefix":"10.1016","volume":"239","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6933-9921","authenticated-orcid":false,"given":"Robert D.","family":"Sandler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Bourke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2818-2379","authenticated-orcid":false,"given":"Sarah","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2813-7557","authenticated-orcid":false,"given":"Jocelyn","family":"Choyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5249-5100","authenticated-orcid":false,"given":"Thom","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Doe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Dooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Echevarria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5338-3572","authenticated-orcid":false,"given":"Penny","family":"Galey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4891-5691","authenticated-orcid":false,"given":"Giles","family":"Fitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lana Y.H.","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8978-2840","authenticated-orcid":false,"given":"Julia A.","family":"Nightingale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Whitehouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Warnock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4017-4588","authenticated-orcid":false,"given":"David","family":"Waine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5326-0258","authenticated-orcid":false,"given":"Nick","family":"Withers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe Hui","family":"Hoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1658-881X","authenticated-orcid":false,"given":"Martin J.","family":"Wildman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10059","key":"10.1016\/j.rmed.2025.107995_bib1","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet."},{"issue":"3","key":"10.1016\/j.rmed.2025.107995_bib2","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","article-title":"Worldwide rates of diagnosis and effective treatment for cystic fibrosis","volume":"21","author":"Guo","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.rmed.2025.107995_bib3","series-title":"UK Cystic Fibrosis Registry Annual Data Report 2022","year":"2023"},{"key":"10.1016\/j.rmed.2025.107995_bib4","series-title":"UK Cystic Fibrosis Registry Annual Data Report 2021","year":"2022"},{"issue":"2","key":"10.1016\/j.rmed.2025.107995_bib5","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","article-title":"ECFS best practice guidelines: the 2018 revision","volume":"17","author":"Castellani","year":"2018","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.rmed.2025.107995_bib6","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","article-title":"CFTR modulators: the changing Face of cystic fibrosis in the era of precision medicine","volume":"10","author":"Lopes-Pacheco","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"19","key":"10.1016\/j.rmed.2025.107995_bib7","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.rmed.2025.107995_bib8","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.rmed.2025.107995_bib9","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1136\/thoraxjnl-2017-210473","article-title":"The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers","volume":"73","author":"Rowbotham","year":"2018","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2025.107995_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1163391","article-title":"Real-world disparities and ethical considerations with access to CFTR modulator drugs: mind the gap","volume":"14","author":"Zampoli","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.rmed.2025.107995_bib11","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.jcf.2022.04.007","article-title":"Current prices versus minimum costs of production for CFTR modulators","volume":"21","author":"Guo","year":"2022","journal-title":"J. Cyst. Fibros."},{"issue":"4","key":"10.1016\/j.rmed.2025.107995_bib13","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jcf.2023.02.004","article-title":"Elexacaftor\/tezacaftor\/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del","volume":"22","author":"Lopez","year":"2023","journal-title":"J. Cyst. Fibros."},{"issue":"5","key":"10.1016\/j.rmed.2025.107995_bib14","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jcf.2012.03.009","article-title":"Risk factors for rate of decline in FEV1 in adults with cystic fibrosis","volume":"11","author":"Konstan","year":"2012","journal-title":"J. Cyst. Fibros."},{"issue":"3","key":"10.1016\/j.rmed.2025.107995_bib15","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jcf.2023.02.012","article-title":"When triple therapy is not working: a reverse iceberg perspective","volume":"22","author":"Castellani","year":"2023","journal-title":"J. Cyst. Fibros."},{"issue":"1","key":"10.1016\/j.rmed.2025.107995_bib16","article-title":"The CFHealthHub learning health system: using real-time adherence data to support a community of practice to deliver continuous improvement in an archetypal long-term condition","volume":"11","author":"Sandler","year":"2022","journal-title":"Healthcare (Basel)"},{"issue":"1","key":"10.1016\/j.rmed.2025.107995_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40814-020-00739-2","article-title":"Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub","volume":"7","author":"Arden","year":"2021","journal-title":"Pilot Feasibility Stud"},{"issue":"5","key":"10.1016\/j.rmed.2025.107995_bib18","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1136\/thoraxjnl-2021-217594","article-title":"Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial","volume":"77","author":"Wildman","year":"2022","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2025.107995_bib19","series-title":"Standards for the Clinical Care of Children and Adults with Cystic Fibrosis in the UK","year":"2024"},{"issue":"4","key":"10.1016\/j.rmed.2025.107995_bib20","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/aje\/153.4.345","article-title":"Predictive 5-year survivorship model of cystic fibrosis","volume":"153","author":"Liou","year":"2001","journal-title":"Am. J. Epidemiol."},{"issue":"10","key":"10.1016\/j.rmed.2025.107995_bib21","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/oxfordjournals.aje.a008664","article-title":"Determinants of mortality from cystic fibrosis in Canada, 1970-1989","volume":"143","author":"Corey","year":"1996","journal-title":"Am. J. Epidemiol."},{"issue":"6","key":"10.1016\/j.rmed.2025.107995_bib22","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/0895-4356(88)90063-7","article-title":"A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto","volume":"41","author":"Corey","year":"1988","journal-title":"J. Clin. Epidemiol."},{"issue":"2","key":"10.1016\/j.rmed.2025.107995_bib23","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S2213-2600(16)30465-9","article-title":"A little CFTR can change a lot: slowing cystic fibrosis progression","volume":"5","author":"Rowe","year":"2017","journal-title":"Lancet Respir. Med."},{"issue":"5","key":"10.1016\/j.rmed.2025.107995_bib24","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jada.2008.02.020","article-title":"Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review","volume":"108","author":"Stallings","year":"2008","journal-title":"J. Am. Diet. Assoc."},{"key":"10.1016\/j.rmed.2025.107995_bib25","unstructured":"Cystic Fibrosis Foundation. Maintaining Healthy Weight With Cystic Fibrosis 2020 [Available from: https:\/\/www.cff.org\/sites\/default\/files\/2021-10\/Maintaining-Healthy-Weight-With-Cystic-Fibrosis.pdf."},{"issue":"3","key":"10.1016\/j.rmed.2025.107995_bib26","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.0740","article-title":"Association of body mass index with clinical outcomes in patients with cystic fibrosis: a systematic review and meta-analysis","volume":"5","author":"Nagy","year":"2022","journal-title":"JAMA Netw. Open"},{"issue":"7","key":"10.1016\/j.rmed.2025.107995_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10071527","article-title":"Real-world outcomes of ivacaftor treatment in people with cystic fibrosis: a systematic review","volume":"10","author":"Duckers","year":"2021","journal-title":"J. Clin. Med."},{"issue":"4","key":"10.1016\/j.rmed.2025.107995_bib28","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s13142-015-0315-2","article-title":"Self-report measures of medication adherence behavior: recommendations on optimal use","volume":"5","author":"Stirratt","year":"2015","journal-title":"Transl Behav Med"},{"issue":"5","key":"10.1016\/j.rmed.2025.107995_bib29","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jcf.2015.05.009","article-title":"Electronic monitoring reveals highly variable adherence patterns in patients prescribed ivacaftor","volume":"14","author":"Siracusa","year":"2015","journal-title":"J. Cyst. Fibros."},{"issue":"2","key":"10.1016\/j.rmed.2025.107995_bib30","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jcf.2021.09.007","article-title":"Using a learning health system to understand the mismatch between medicines supply and actual medicines use among adults with cystic fibrosis","volume":"21","author":"Bevan","year":"2022","journal-title":"J. Cyst. Fibros."},{"issue":"suppl 12","key":"10.1016\/j.rmed.2025.107995_bib31","first-page":"53","article-title":"Is there a role for sweat chloride levels as a marker of clinical response to Elexacaftor\/Tezacaftor\/Ivacaftor in Cystic Fibrosis patients?","volume":"9","author":"Pereira Fernandes","year":"2023","journal-title":"ERJ Open Research"},{"issue":"1","key":"10.1016\/j.rmed.2025.107995_bib32","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jcf.2016.10.002","article-title":"Correlation of sweat chloride and percent predicted FEV 1 in cystic fibrosis patients treated with ivacaftor","volume":"16","author":"Fidler","year":"2017","journal-title":"J. Cyst. Fibros."},{"issue":"2","key":"10.1016\/j.rmed.2025.107995_bib33","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcf.2008.09.007","article-title":"High treatment burden in adults with cystic fibrosis: challenges to disease self-management","volume":"8","author":"Sawicki","year":"2009","journal-title":"J. Cyst. Fibros."},{"issue":"6","key":"10.1016\/j.rmed.2025.107995_bib34","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1016\/j.chest.2021.06.039","article-title":"Real-world adherence among adults with cystic fibrosis is low: a retrospective analysis of the CFHealthHub digital learning health system","volume":"160","author":"Hoo","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2025.107995_bib35","first-page":"CD001021","article-title":"Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis","volume":"11","author":"Smith","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.rmed.2025.107995_bib36","article-title":"Dornase alfa for cystic fibrosis","volume":"3","author":"Yang","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.rmed.2025.107995_bib37","first-page":"CD001506","article-title":"Nebulised hypertonic saline for cystic fibrosis","volume":"9","author":"Wark","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"issue":"6","key":"10.1016\/j.rmed.2025.107995_bib38","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/MCP.0b013e3283659f45","article-title":"The impact of medication adherence on lung health outcomes in cystic fibrosis","volume":"19","author":"Eakin","year":"2013","journal-title":"Curr. Opin. Pulm. Med."},{"issue":"2","key":"10.1016\/j.rmed.2025.107995_bib39","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1378\/chest.09-3074","article-title":"Accurate assessment of adherence: self-report and clinician report vs electronic monitoring of nebulizers","volume":"140","author":"Daniels","year":"2011","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.rmed.2025.107995_bib40","article-title":"Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis","volume":"3","author":"Dawson","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.rmed.2025.107995_bib41","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1586\/17476348.2015.995640","article-title":"The problems of antibiotic resistance in cystic fibrosis and solutions","volume":"9","author":"L\u00f3pez-Causap\u00e9","year":"2015","journal-title":"Expert Rev Respir Med"},{"issue":"12","key":"10.1016\/j.rmed.2025.107995_bib42","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2337\/dc10-1768","article-title":"Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.rmed.2025.107995_bib43","first-page":"157","article-title":"Cystic fibrosis-related diabetes: links, challenges, and future directions","volume":"5","author":"Sheikh","year":"2015","journal-title":"Res. Rep. Endocr. Disord."},{"issue":"7","key":"10.1016\/j.rmed.2025.107995_bib45","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1164\/rccm.201503-0578OC","article-title":"Sustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data","volume":"192","author":"Sawicki","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2025.107995_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2023.107414","article-title":"Biologics in severe asthma: a pragmatic approach for choosing the right treatment for the right patient","volume":"218","author":"Rogers","year":"2023","journal-title":"Respir. Med."},{"issue":"20","key":"10.1016\/j.rmed.2025.107995_bib47","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJM199211123272002","article-title":"Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans affairs stroke prevention in nonrheumatic atrial fibrillation investigators","volume":"327","author":"Ezekowitz","year":"1992","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.rmed.2025.107995_bib48","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1136\/annrheumdis-2015-207526","article-title":"Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update","volume":"75","author":"Stoffer","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.rmed.2025.107995_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/S1569-1993(21)01709-4","article-title":"284: explaining the efficacy-effectiveness gap for ivacaftor: the potential impact of adherence to maintenance inhaled therapy on outcomes","volume":"20","author":"Daniels","year":"2021","journal-title":"J. Cyst. Fibros."},{"issue":"4","key":"10.1016\/j.rmed.2025.107995_bib50","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S2213-2600(22)00434-9","article-title":"Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials","volume":"11","author":"Mayer-Hamblett","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.rmed.2025.107995_bib51","unstructured":"Cystic Fibrosis Trust. CF Storm 2021 [Available from: https:\/\/www.cysticfibrosis.org.uk\/get-involved\/clinical-trials\/trialstracker\/138613."},{"issue":"6","key":"10.1016\/j.rmed.2025.107995_bib52","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.chest.2022.07.008","article-title":"Treatment preference among people with cystic fibrosis: the importance of reducing treatment burden","volume":"162","author":"Cameron","year":"2022","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.rmed.2025.107995_bib53","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.1016\/j.chest.2022.11.046","article-title":"Future discounting bias and scenarios without lock-step FEV","volume":"163","author":"Hoo","year":"2023","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2025.107995_bib54","series-title":"Good Medical Practice 2024","year":"2024"},{"key":"10.1016\/j.rmed.2025.107995_bib55","first-page":"1","article-title":"\"I think most people feel like healthcare professionals tell them to take their treatments and judge them for not taking them\": reflexive thematic analysis of the views of adults with cystic fibrosis on how treatment adherence is discussed in healthcare","author":"Dawson","year":"2023","journal-title":"Psychol. Health"},{"issue":"1","key":"10.1016\/j.rmed.2025.107995_bib56","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/ppul.1950080107","article-title":"Variability of pulmonary function tests in cystic fibrosis","volume":"8","author":"Cooper","year":"1990","journal-title":"Pediatr. Pulmonol."},{"issue":"11","key":"10.1016\/j.rmed.2025.107995_bib57","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/ppul.20924","article-title":"Reproducibility of spirometry during cystic fibrosis pulmonary exacerbations","volume":"43","author":"Sanders","year":"2008","journal-title":"Pediatr. Pulmonol."},{"issue":"10","key":"10.1016\/j.rmed.2025.107995_bib58","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1136\/thoraxjnl-2011-200953","article-title":"Understanding the natural progression in %FEV1 decline in patients with cystic fibrosis: a longitudinal study","volume":"67","author":"Taylor-Robinson","year":"2012","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2025.107995_bib59","first-page":"S128","article-title":"P209 Personalised data-Linkage Understanding Treatment Optimisation (PLUTO) in the CFHealthHub Learning Health System: understanding how much is enough for normal life expectancy in the post-modulator era","volume":"22","author":"Sandler","year":"2023","journal-title":"J. Cyst. Fibros."}],"updated-by":[{"DOI":"10.1016\/j.rmed.2025.108016","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000}}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611125000575?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611125000575?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T02:12:59Z","timestamp":1745719979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611125000575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":57,"alternative-id":["S0954611125000575"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2025.107995","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimising outcomes for adults with cystic fibrosis taking CFTR modulators by individualising care: Personalised data linkage to understand treatment optimisation (PLUTO), a novel clinical framework","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2025.107995","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107995"}}